Results from a Phase 3 study showed ixekizumab significantly improved the signs and symptoms of non-radiographic axial spondyloarthritis in patients…
Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer and editor. She is also a pharmacist at New York Presbyterian Hospital–Lower Manhattan campus. She has been a past guest lecturer at Touro College of Pharmacy in New York City for the Medical Writing elective. Dr Kaufman is a member of the New York City Society of Health-Systems Pharmacy, the New York State Council of Health-System Pharmacists, the Academy of Managed Care Pharmacy (AMCP)—Northeast Region Affiliate Chapter, the American Society of Consultant Pharmacists and the Empire State-Metropolitan NY Chapter of the American Medical Writers Association. She received her BS in Pharmacy from the University of Rhode Island (URI) College of Pharmacy and her Doctor of Pharmacy degree from Massachusetts College of Pharmacy and Allied Health Sciences in Boston. She also completed a Drug Information Fellowship at the URI Drug Information Center/Roger Williams Medical Center in Providence, R.I. Dr Kaufman is a registered pharmacist and is a Board-Certified Geriatric Pharmacist.
Articles by Michele B. Kaufman, PharmD, BCGP
IV Meloxicam Stalls at FDA; Plus Health Canada Approves Risankizumab for Plaque Psoriasis
In a second response letter, the FDA has cited the onset and duration of intravenous meloxicam, a non-opioid pain treatment, as concerns that it fails to meet prescriber expectations…
Health Canada Approves Certolizumab Pegol & NICE Issues Guidance for Certolizumab Pegol
Certolizumab pegol has been approved in Canada for treating adults with plaque psoriasis. The U.K. has also issued its final guidance for the treatment’s use…
FDA Approves Certolizumab Pegol for Treating Non-Radiographic Axial SpA
Certolizumab pegol is now FDA approved to treat adults with active non-radiographic axial spondyloarthritis…
FDA Approves New Osteoporosis Medication
Romosozumab-aqqg has been approved in the U.S. for treating postmenopausal women with osteoporosis at high risk of fracture…
Japan Approves Risankizumab for Psoriasis & Psoriatic Arthritis
Japan has approved risankizumab for treating plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis in adults…
Mirikizumab Promising for Plaque Psoriasis
During a 16-week study, patients with plaque psoriasis taking mirikizumab experienced higher response rates and skin clearance compared with placebo…
Health Canada Approves Adalimumab for Chronic Non-Infectious Anterior Uveitis in Pediatric Patients
Health Canada has approved adalimumab for treating chronic non-infectious anterior uveitis in patients 2 years and older…
SM04690 Promising for Knee OA
SM04690, an intra-articular injection for knee OA, will soon enter phase 3 trials to assess its effects on pain, joint function and disease…
FDA Approves Guselkumab Injector
The FDA has approved a single-press, self-injection device for a 100-mg dose of guselkumab for adults with moderate to severe plaque psoriasis…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- …
- 43
- Next Page »